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Attention deﬁcit hyperactivity disorder (ADHD) and autism spectrum
disorder (ASD) share brain function abnormalities during cognitive
ﬂexibility. Serotonin is involved in both disorders, and selective sero-
tonin reuptake inhibitors (SSRIs) can modulate cognitive ﬂexibility
and improve behavior in both disorders. Thus, this study investigates
shared and disorder-speciﬁc brain dysfunctions in these 2 disorders
during reward reversal, and the acute effects of an SSRI on these.
Age-matched boys with ADHD (15), ASD (18), and controls (21)
were compared with functional magnetic resonance imaging (fMRI)
during a reversal task. Patients were scanned twice, under either an
acute dose of Fluoxetine or placebo in a double-blind, placebo-con-
trolled randomized design. Repeated-measures analyses within
patients assessed drug effects. Patients under each drug condition
were compared with controls to assess normalization effects. fMRI
data showed that, under placebo, ASD boys underactivated medial
prefrontal cortex (mPFC), compared with control and ADHD boys.
Both patient groups shared decreased precuneus activation. Under
Fluoxetine, mPFC activation was up-regulated and normalized in
ASD boys relative to controls, but down-regulated in ADHD boys rela-
tive to placebo, which was concomitant with worse task perform-
ance in ADHD. Fluoxetine therefore has inverse effects on mPFC
activation in ASD and ADHD during reversal learning, suggesting dis-
sociated underlying serotonin abnormalities.
Keywords: ADHD, ASD, cognitive ﬂexibility, fMRI, serotonin
Introduction
Attention deﬁcit hyperactivity disorder (ADHD) is a neurode-
velopmental disorder characterized by age-inappropriate
levels of impulsiveness, inattention, and hyperactivity (Ameri-
can Psychiatric Association 1994). Autism spectrum disorder
(ASD) is deﬁned by impairments in communication, social
interaction, and also by restricted and repetitive behaviors
(American Psychiatric Association 1994). ADHD and ASD are
highly comorbid and both disorders share executive function
deﬁcits (Willcutt et al. 2005; Corbett et al. 2009; Rommelse
et al. 2011), including poor cognitive ﬂexibility (Hill 2004; Will-
cutt et al. 2005; Sanders et al. 2008), which has been linked to
repetitive behaviors in ASD (Yerys et al. 2009). The clinical
importance of this behavioral and cognitive overlap has been
highlighted by changes to the upcoming DSM-V, which allows
co-diagnosis of ADHD and ASD (http://www.dsm5.org).
Cognitive ﬂexibility can be measured in switching and rever-
sal tasks, where stimulus-response associations need to be
either changed to new, or reversed to previous stimulus-
response associations, respectively. It is known that the pre-
frontal cortex is involved in many aspects of cognition, and
that the same region can play a role in a number of functions
(Goldman-Rakic et al. 1996; Ashby and Isen 1999). However,
the cognitive processes of switching and reward reversal learn-
ing involve quite different neuronal circuitry. During switching
tasks, healthy children and adults activate inferior frontal
cortex (IFC), dorsolateral prefrontal cortex (DLPFC), anterior
cingulate cortex (ACC), and parietal lobe (Derrfuss et al. 2005;
Loose et al. 2006; Rubia et al. 2006; Ravizza and Carter 2008;
Christakou, Halari, et al. 2009). During reward reversal learn-
ing tasks, in healthy adults, due to the emotional valence of the
reward and punishment present in reward reversal learning
tasks, more medial brain regions, including medial prefrontal
cortex (mPFC), medial orbitofrontal cortex (OFC), and ACC,
are typically recruited (O’Doherty et al. 2001, 2003; Cools et al.
2002; Remijnse et al. 2005; Cohen et al. 2008; Kehagia et al.
2010). Striatal activation is also observed during reward rever-
sal learning due to the role of the striatum in reward-related
habitual learning and stimulus-response associations, with
more ventral striatal regions involved in reversal learning
(Cools et al. 2002; Packard and Knowlton 2002; Remijnse et al.
2005; Yin and Knowlton 2006) and more anterior striatal
regions being implicated in switching (Rubia et al. 2006; Chris-
takou, Halari, et al. 2009).
fMRI studies of switch tasks have found decreased activation
in ADHD children compared with controls in the IFC, temporo-
parietal junction, and striatum (Smith et al. 2006; Rubia, Cubillo,
et al. 2010; Rubia, Halari, et al. 2010). ADHD patients have been
shown to have abnormal medial frontal and precuneus acti-
vation during reward reversal tasks (Finger et al. 2008). In ASD
children, no fMRI study has investigated cognitive ﬂexibility. In
adult ASD, however, 2 studies have reported conﬂicting evi-
dence of decreased activation in the DLPFC, ACC, and basal
ganglia (Shafritz et al. 2008), and increased activation in the IFC
and parietal lobe relative to controls (Schmitz et al. 2006).
5-HT and dopamine interact in the prefrontal cortex, result-
ing in the ﬁne tuning of neuronal responses and better cogni-
tion, particularly in tasks that require the maintenance of
stimulus-response representations (Goldman-Rakic 1999).
There is evidence that 5-HT is involved in reward reversal
learning (Murphy et al. 2002; Evers et al. 2005; Roberts 2011).
Furthermore, there is evidence that 5-HT is involved in the
pathology of both ADHD and ASD.
Thus, polymorphisms of serotonergic genes have been
associated with both ADHD and ASD (Sinzig and Lehmkuhl
© The Author 2014. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which
permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.
permissions@oup.com
Cerebral Cortex July 2015;25:1757–1770
doi:10.1093/cercor/bht365
Advance Access publication January 22, 2014
 at K
ing's College London - Journals D






2007; Rommelse et al. 2010), and there is evidence that a poly-
morphism of the 5-HT transporter gene may play a role in the
ADHD symptoms observed in ASD (Gadow et al. 2013). More-
over, biochemical serotonergic dysfunction has been impli-
cated in both ADHD (Oades 2007) and ASD (Zafeiriou et al.
2009). In children with ADHD, there is evidence for decreased
platelet 5-HT levels (Spivak et al. 1999) and increased ADHD
behavior after a reduction in 5-HT (Zepf et al. 2008, 2010).
Conversely, one-third of the individuals with ASD have abnor-
mally elevated 5-HT platelet levels (Piven et al. 1991; Mulder
et al. 2004; Hranilovic et al. 2007). In addition, in ASD, abnor-
mal 5-HT synthesis (Chugani et al. 1997, 1999), 5-HT transpor-
ter (Makkonen et al. 2008; Nakamura et al. 2010), and 5-HT2A
receptor binding (Murphy et al. 2006) have also been reported.
Clinical trials of Fluoxetine in children with ASD have shown
improvement in communication, social interaction, and stereo-
typed behaviors (DeLong et al. 1998, 2002; Hollander et al.
2005; Carrasco et al. 2012), although effects are small (Williams
et al. 2010). In addition, SSRIs have shown to increase meta-
bolic and neurofunctional activity in adults with ASD in areas
mediating reward reversal learning such as OFC/mPFC, ACC,
and striatum (Mitchell et al. 2008; Freyer et al. 2009), which
was associated with reduced obsessive behavior (Buchsbaum
et al. 2001; Dichter et al. 2010).
In ADHD children, Fluoxetine monotherapy has been
shown to signiﬁcantly improve inattentiveness and hyperactiv-
ity in noncomorbid groups (Barrickman et al. 1991), as well as
in groups with co-morbid bipolar disorder (Quintana et al.
2007). Fluoxetine also appears to moderate the efﬁcacy of
stimulant medication, as evidenced by the ﬁnding that com-
bined Fluoxetine–Methylphenidate treatment reduces ADHD
symptoms in co-morbid ADHD children (Gammon and Brown
1993; Findling 1996). There is evidence that 5-HT and dopa-
mine interact, in particular, with respect to impulsiveness
(Dalley and Roiser 2012) and the serotonergic system has been
shown to play a key regulatory role in dopamine release
(Sibley et al. 2007; Di Matteo et al. 2008), which is typically low
in ADHD (Volkow et al. 1998; del Campo et al. 2011). The
importance of 5-HT-dopamine interactions in ADHD is further
reinforced by evidence for abnormal ratios and correlations
between 5-HT and dopamine levels in children with ADHD
(Castellanos et al. 1994; Oades et al. 1998). There is also evi-
dence that response to stimulants is mediated by 5-HT in animal
(Gainetdinov et al. 1999) and human studies as an association
between serotonergic genes and Methylphenidate response has
been observed (McGough et al. 2009; Banerjee et al. 2012). In
addition, the co-administration of 5-HT and dopamine amino
acids precursors in children with ADHD has been shown to lead
to a signiﬁcant improvement in symptoms (Hinz et al. 2011).
Therefore, when used in combination, Fluoxetine may lead
to better regulation of the increased dopamine induced by
Methylphenidate, leading to clinical improvement (Barrickman
et al. 1991; Gammon and Brown 1993; Findling 1996; Quintana
et al. 2007). This is in line with the seminal animal study of
Gainetdinov et al. (1999) which showed that, in mice, the effect
of Methylphenidate was dependent on 5-HT.
In conclusion, there is evidence for impaired cognitive ﬂexi-
bility and underlying neurofunctional brain mechanisms in
ADHD (Willcutt et al. 2005; Smith et al. 2006; Finger et al.
2008; Rubia, Cubillo, et al. 2010; Rubia, Halari, et al. 2010) and
in ASD (Hill 2004; Schmitz et al. 2006; Sanders et al. 2008;
Shafritz et al. 2008). Furthermore, both disorders have shown
5-HT abnormalities (Piven et al. 1991; Spivak et al. 1999;
Mulder et al. 2004; Hranilovic et al. 2007; Oades 2007; Zafeir-
iou et al. 2009), which may possibly underlie these cognitive
ﬂexibility deﬁcits. In addition, Fluoxetine has shown to
improve behavior in these 2 disorders (Barrickman et al. 1991;
Gammon and Brown 1993; DeLong et al. 1998, 2002; Hollan-
der et al. 2005; Quintana et al. 2007; Carrasco et al. 2012), and
to modify cognitive ﬂexibility and underlying neural networks
in healthy subjects (Evers et al. 2005; Roberts 2011).
The aim of this study was therefore to investigate (1) shared
and disorder-speciﬁc brain abnormalities in adolescents with
ADHD and those with ASD during reward reversal learning
and (2) shared and disorder-speciﬁc neurofunctional effects of
an acute dose of Fluoxetine on this function in both disorders.
Based on prior evidence (Smith et al. 2006; Finger et al.
2008; Shafritz et al. 2008; Rubia, Cubillo, et al. 2010; Rubia,
Halari, et al. 2010), we hypothesized that, under placebo, both
disorders would show abnormal switching related activation in
compared with controls, with more prominent IFC-striatal deﬁ-
cits in ADHD, and more prominent DLPFC and mPFC abnormal-
ities in ASD. We also hypothesized that Fluoxetine would
normalize these neurofunctional abnormalities in both disorders.
Materials and Methods
Participants
Fifty-four right-handed males (assessed with the Edinburgh Handed-
ness Inventory; Oldﬁeld 1971; 21 controls, 15 with ADHD, and 18 with
ASD), aged 10–17 years, IQ >70 (assessed with the Wechsler Abbre-
viated Scale of Intelligence-Revised; Wechsler 1999), participated.
Thirty-two ADHD boys were recruited in total; however, 10 boys
dropped out of the study due to their dislike of the MRI scanner, 3
were excluded due to co-morbidities (despite the fact we explicitly
aimed to recruit only noncomorbid cases), 1 did not reach the diagnos-
tic criteria for the combined subtype of ADHD, 1 was excluded due to
poor task performance, and 2 were excluded due to high levels of
motion.
ADHD boys had a DSM-IV diagnosis of noncomorbid ADHD, inat-
tentive/hyperactive-impulsive combined subtype, as assessed by an
experienced child psychiatrist using the standardized Maudsley diag-
nostic interview (Goldberg and Murray 2002). They scored above clini-
cal threshold for ADHD on both the Strengths and Difﬁculties
Questionnaire (SDQ) (Goodman and Scott 1999) and the Conners’
Parent Rating Scale-Revised (CPRS-R; Conners et al. 1998) (1 boy was
below cut-off on SDQ, but had diagnostic conﬁrmation from a child
psychiatrist). Three of the ADHD boys were medication-naïve, 1 had
ceased taking Methylphenidate 3 months prior to the study, and 11
were on chronic stimulants, but had a 48-h medication washout prior
to scanning. ADHD boys were excluded if they scored >15 on the
Social Communication Questionnaire (SCQ; Rutter et al. 2003).
Forty-four ASD boys were recruited in total. Of these, 7 boys
dropped out of the study due to their dislike of the MRI scanner, 14
were excluded due to co-morbidities, 1 was excluded due to neurologi-
cal abnormalities, 2 were excluded due to SSRI use, and 2 were ex-
cluded due to high levels of motion. ASD diagnosis was made using
ICD-10 diagnostic criteria (World Health Organisation 1994) and con-
ﬁrmed by the Autism Diagnostic Interview-Revised (ADI; Lord et al.
1994) and the Autism Diagnostic Observation Schedule (ADOS; Lord
et al. 2000). All ASD subjects were medication-naïve apart from 1
patient, who took melatonin (but underwent 2-week medication
washout). ASD exclusion criteria included a score of >7 on the hyper-
activity/inattention subscale of the SDQ.
DSM-IV as opposed to DSM-V criteria was used to conﬁrm both
ADHD and ASD diagnoses, as DSM-V was not available for clinical use
at the time of testing. As previously mentioned, DSM-V allows co-
diagnosis of ADHD and ASD and therefore would have enabled easier
identiﬁcation and exclusion of comorbid cases. However, rigorous
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screening ensured that clinical levels of ADHD and ASD traits were not
present in ASD or ADHD participants, respectively.
Patients were recruited from local clinics and support groups. They
were scanned twice in a double-blind, randomized, placebo-controlled
design, using a Latin square randomization design for counter-
balanced effects. Due to the half-life of Fluoxetine (1–3 days) and its
metabolite Norﬂuoxetine (5–16 days) (Wong et al. 1995), each scan
was 3–4 weeks apart. To ensure that Fluoxetine had reached its peak
plasma levels, shown to be after 5–8 h (Wong et al. 1995), patients
were scanned 5 h after administration. Liquid Fluoxetine was titrated to
age and weight as follows: boys between 10–13 years and <30 kg re-
ceived 8 mg, those >30 kg received 10 mg. Boys between 14–17 years
and <30 kg received 10 mg, and those >30 kg received 15 mg. Placebo
was peppermint water, which was similar in taste to Fluoxetine and
measured to the equivalent volume.
Twenty-one handedness and age-matched controls were recruited
by advertisement. They all scored below clinical thresholds on the
SDQ, SCQ, and CPRS. Controls were scanned only once. Drug/alcohol
dependency was an exclusion criterium for all participants.
Written informed consent/assent was given for all participants. The
study was approved by the local ethics committee. Participants were
paid £50 for each scan.
fMRI Paradigm—Reward Reversal Learning
Subjects practiced the task once prior to each scan. Our fMRI adap-
tation is similar to the probabilistic reward reversal learning task em-
ployed by Cools et al. (2002). The semi-self-paced reward reversal
learning task requires subjects to learn a stimulus-response association
by reward and punishment and to reverse their response when the
stimulus-reward contingency changes unexpectedly. Images of a car
and a spaceship are displayed simultaneously on the left and right side
(randomized) of a black screen for 1950 ms. The subject has to choose
with a left or right button press the correct choice, indicated by feed-
back via an image of a 50 pence piece and a green happy smiley,
whereas the incorrect choice is indicated by an image of a crossed-out
50 pence piece and a red unhappy smiley, both displayed after the
choice for 950 ms. There is a 100-ms gap between each trial leading to
an intertrial interval of 3 s. Reversal of the stimulus-reward contingency
occurs after 4–6 consecutive correct responses (i.e., if the car is re-
warded and associated with a positive feedback, when a reversal
occurs the car is suddenly no longer rewarded, but the spaceship is)
(Fig. 1). The task ends after 20 reversal trials or after 20 min, whichever
condition is met ﬁrst. Zero to 2 probabilistic error trials (PETs), where
a negative feedback is given for a correct response, are randomly inter-
spersed between reversal trials to prevent subjects from predicting an
upcoming reversal trial. PETs are at least 3 trials apart from other PETs
and reversal trials. Brain activation to PETs are subtracted from brain
activation to the ﬁnal reversal error before a correct response. This
stringent contrast captures the point at which subjects learn to reverse
their response, and controls for the brain response to the punishment
given in the negative feedback in both trials. This contrast has been
used in previous fMRI studies of reward reversal learning (Cools et al.
2002; Remijnse et al. 2005). The main dependent variable is the
number of perservative errors made after a reversal trial.
Analysis of Performance Data
Two analyses of variance (ANOVAs) compared perseverative errors
between controls and patients under either placebo or Fluoxetine. A
repeated-measures ANOVA was conducted within the patient groups
with group as an independent factor and drug as a repeated measure
to test for group by medication interaction effects on performance.
Bonferroni correction was used to correct for multiple comparisons.
fMRI Image Acquisition
Gradient-echo echo-planar MR imaging (EPI) data were acquired on a
General Electric Signa 3-T Horizon HDx system at the Centre For Neu-
roimaging Sciences, Institute of Psychiatry, UK. A semi-automated
quality control procedure ensured consistent image quality (Simmons
et al. 1999). A quadrature birdcage headcoil was used for radio
frequency transmission and reception. In each of 23 noncontiguous
planes parallel to the anterior–posterior commissure, 800 T2*-weighted
MR images depicting blood oxygen level-dependent (BOLD) contrast
covering the whole brain were acquired with time echo (TE) = 30 ms,
time repetition (TR) = 1.5 s, ﬂip angle = 70°, in-plane voxel size = 3
mm, slice thickness = 5.5 mm (including slice skip = 0.5 mm), and total
acquisition time = 20 min. This EPI dataset provided almost complete
brain coverage. A whole-brain high-resolution structural scan, (inver-
sion recovery gradient-echo-planar image) on which to superimpose
the individual activation maps, was also acquired in the intercommis-
sural plane with TE = 30 ms, TR = 3 s, ﬂip angle = 90°, 43 slices, slice
thickness = 3.0 mm, slice skip = 0.3 mm, and in-plane voxel-size =
1.875 mm. The majority of the subjects conducted 3 more fMRI tasks in
the same scanning session, which are not analyzed here. Total scan-
ning time was 1 h.
fMRI Image Analysis
The XBAM software package was used (http://www.brainmap.co.uk;
Brammer et al. 1997), which makes no normality assumptions (often
violated in fMRI data), but instead uses median statistics to control
outlier effects and permutation rather than normal theory-based infer-
ence. This method of fMRI analysis has been shown to be give excel-
lent Type II error control, and there is evidence that permutation
testing results in better sensitivity when compared with the more com-
monly used theory-based methods of analysis (Thirion et al. 2007).
Individual Analysis
fMRI data were ﬁrst processed to minimize motion-related artifacts
(Bullmore, Brammer, et al. 1999). A 3-dimensional (3D) volume con-
sisting of the average intensity at each voxel over the whole experiment
was calculated and used as a template. The 3D image volume at each
time point was then realigned to this template by computing the com-
bination of rotations (around the x, y, and z axes) and translations (in
x, y, and z) that maximized the correlation between the image intensi-
ties of the volume in question and the template (rigid-body regis-
tration). Following realignment, data were then smoothed using a
Gaussian ﬁlter (full-width at half-maximum, 7.2 mm) to improve the
signal-to-noise characteristics of the images. After motion correction,
global detrending, and spin-excitation history correction, time series
analysis for each subject was based on a wavelet-based data resampling
method for fMRI data (Bullmore, Suckling, et al. 1999; Bullmore et al.
2001). At the individual-subject level, a standard general linear model-
ing approach was used to obtain estimates of the response size (beta)
to each the reward reversal learning task conditions (ﬁnal reversal
error and probabilistic error) against an implicit baseline (repeat trials)
and again for the higher level contrast of ﬁnal reversal error trials
minus PETs. Brieﬂy, we ﬁrst convolved the main experimental con-
ditions (ﬁnal reversal and PETs; each separately contrasted with repeat
trials) and the higher level contrast (ﬁnal reversal error trials minus
PETs) with 2 Poisson model functions (peaking at 4 and 8 s). We then
calculated the weighted sum of these 2 convolutions that gave the best
ﬁt (least squares) to the time series at each voxel. A goodness-of-ﬁt stat-
istic (the SSQ ratio) was then computed at each voxel consisting of the
ratio of the sum of squares of deviations from the mean intensity value
due to the model (ﬁtted time series) divided by the that of squares due
to the residuals (original time series minus model time series). The ap-
propriate null distribution for assessing signiﬁcance of any given SSQ
ratio was established using a wavelet-based data re-sampling method
(Bullmore et al. 2001) and applying the model-ﬁtting process to the re-
sampled data. This process was repeated 20 times at each voxel and
the data combined over all voxels, resulting in 20 null parametric maps
of SSQ ratio for each subject, which were combined to give the overall
null distribution of SSQ ratio. The same permutation strategy was
applied at each voxel to preserve spatial correlation structure in the
data. Activated voxels, at a <1 level of Type I error, were identiﬁed
through the appropriate critical value of the SSQ ratio from the null dis-
tribution (Brammer et al. 1997; Bullmore, Suckling, et al. 1999). Indi-
vidual SSQ ratio maps were then transformed into standard space, ﬁrst
by rigid-body transformation of the fMRI data into a high-resolution
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inversion recovery image of the same subject, and then by afﬁne trans-
formation onto a Talairach template (Talairach and Tournoux 1988).
Group Analysis
A group activation map was produced for the experimental condition
(ﬁnal reversal error—probabilistic error) by calculating the median ob-
served SSQ ratio over all subjects at each voxel in standard space and
testing them against the null distribution of median SSQ ratios com-
puted from the identically transformed wavelet re-sampled data
(Brammer et al. 1997; Bullmore et al. 2001). The voxel-level threshold
was ﬁrst set to 0.05 to give maximum sensitivity and to avoid Type II
errors. Next, a cluster-level threshold was computed for the resulting
3D voxel clusters. The necessary combination of voxel and cluster-level
thresholds was not assumed from theory, but rather was determined
by direct permutation for each data set, giving excellent Type II error
control (Bullmore, Suckling, et al. 1999). Cluster mass rather than a
cluster extent threshold was used, to minimize discrimination against
possible small, strongly responding foci of activation (Bullmore, Suck-
ling, et al. 1999). In all group activation analyses, less than one false-
positive activation locus was expected for P < 0.05 at the voxel level
and P < 0.01 at the cluster level.
ANCOVA Between-Group Difference Analyses
For the between-group comparisons between controls and patients
under either placebo or Fluoxetine, 1-way ANCOVAs with group as
factor and rotational and translation movement in Euclidian 3D space
as a covariate were conducted using randomization-based tests for
voxel or cluster-wise differences as described in detail elsewhere (Bull-
more, Suckling, et al. 1999; Bullmore et al. 2001). For these
between-group comparisons, a P-value of P < 0.05 was used for voxel
and P < 0.02 for cluster comparisons to achieve an optimal balance
between Type II and Type I error. Then, the standardized BOLD
response values (SSQ ratios) for each participant were extracted for
each of the signiﬁcant clusters of the 3-group ANCOVAs, and post hoc
t-tests (correcting for multiple comparisons using least signiﬁcant
difference, LSD) were conducted to identify the direction of the
between-group differences.
ANCOVAWithin-Patient Interaction Effects
To investigate the group by drug interaction effects between placebo
and Fluoxetine within the patient groups, a 2 × 2 ANCOVA (2 medi-
cation conditions and 2 groups) with rotational and translation move-
ment in Euclidian 3D space as a covariate was conducted using
randomization-based testing for voxel or cluster-wise differences as de-
scribed elsewhere (Bullmore et al. 2001). Less than one false-positive
3D cluster was expected at P < 0.05 at the voxel level and P < 0.01 at
the cluster level. Statistical measures of BOLD response for each par-
ticipant were then extracted in each of the signiﬁcant clusters, and post
hoc t-tests (correcting for multiple comparisons with LSD) were con-
ducted to identify the direction of the interaction effects.
Normalization Effects
To test for the statistical signiﬁcance of any apparent normalization
effects of Fluoxetine on case-control activation differences observed
under placebo, we used repeated-measures t-tests on the extracted
BOLD responses during each medication condition for each of the
clusters shown to be signiﬁcantly different in the comparison between
controls and patients during placebo. We conducted this test only




ANOVAs showed no signiﬁcant group differences in age
[median age: controls: 13.7 (SD = 2.6); ADHD: 15.2 (SD = 1.8);
ASD: 15.1 (SD = 1.9)], but did in IQ (Fdf=2,53 = 7, P < 0.002),
Figure 1. Reward reversal learning task: subjects select an image (right/left) by pressing the corresponding button (right/left). If is the choice is correct/incorrect, positive/negative
feedback is given. Once the subject has made 4–6 correct responses, the stimulus-reward contingency is reversed. PETs, where incorrect feedback is given for a correct response,
are included to prevent subjects from predicting an upcoming reversal trial. The task contains on average 20 reversal trials with 20 interspersed PET trials.
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which was signiﬁcantly lower in ADHD relative to control and
ASD boys (P < 0.005), who did not differ from each other.
ADHD children typically have lower IQ than their healthy
peers (Bridgett and Walker 2006). Therefore, IQ was not covar-
ied, as when the covariate is intrinsic to the condition, and
differs between groups whowere not randomly selected, it vio-
lates ANCOVA assumptions (Dennis et al. 2009). Nonetheless,
to assess the potential impact of IQ on group differences and
group by medication interaction effects, the analyses were re-
peated with IQ as a covariate.
Performance Data
ANOVA between controls and patients under placebo showed
no signiﬁcant group effect (Fdf=2,53 = 2, P = 0.170), although
both patient groups made numerically more errors than con-
trols with a relatively large effect size of 0.67 for ADHD and a
medium effect size of 0.48 for ASD. When patients were under
Fluoxetine, there was a signiﬁcant group effect for persevera-
tive errors (Fdf=2,53 = 4, P < 0.05) that were signiﬁcantly higher
in ADHD under Fluoxetine relative to controls (P < 0.005),
which survived Bonferroni correction for multiple comparisons
(P < 0.05) [mean perseverative errors: controls: 1.4 (SD = 0.3);
ADHD placebo: 1.7 (SD = 0.5); ADHD Fluoxetine: 1.8 (SD = 0.4);
ASD placebo: 1.7 (SD = 0.6); ASD Fluoxetine: 1.6 (0.4)].
However, for the within-patient analyses, no interaction effects
were observed between groups (ADHD; ASD) and medication
status (placebo; ﬂuoxetine), suggesting that ﬂuoxetine had no
differential effect on performance in either group.
fMRI Data
Movement
Repeated-measures ANOVAs using group as an independent
factor and maximum x, y, and z rotation or maximum x, y, and
z translation as repeated measures showed that there were no
signiﬁcant group by movement interaction effects in rotation
(Fdf=4,102 = 2, P = n.s.) or translation (Fdf=4,102 = 2, P = n.s).
Nevertheless, to eliminate any potential effects of nonsigniﬁ-
cant variance in motion, 3D Euclidean motion parameters
were used as covariates in fMRI analysis.
Group Brain Activation Maps
Final Reversal Error—Probabilistic Error
Controls. Controls activated a bilateral network consisting of
mPFC, supplementary motor area (SMA), ACC, precentral/
postcentral gyri, inferior/middle/superior frontal cortices,
basal ganglia, thalamus, midbrain, and posterior cingulate
cortex (PCC)/precuneus (Fig. 2A)
Attention Deﬁcit Hyperactivity Disorder. Under placebo,
ADHD subjects activated mPFC/ACC, left precentral/postcentral
gyri, right middle frontal cortex, bilateral IFC/insula, putamen,
and left inferior- and right superior-parietal lobes. Under
Fluoxetine, ADHD subjects activated SMA, left superior parietal
lobe, and right hippocampal gyrus (Fig. 2B).
Autism Spectrum Disorder. Under placebo, ASD subjects
activated bilateral IFC/caudate/putamen and a right hemispheric
network consisting of precentral/postcentral gyrus, inferior/
superior parietal lobe, precuneus, and fusiform gyrus/cerebellum.
Under Fluoxetine, ASD subjects activated a right hemispheric
network consisting of middle/superior frontal cortex, superior
parietal lobe, and precuneus (Fig. 2C).
Between-Group Differences Between Controls
and Patients Under Placebo
ANCOVA between controls and patients under placebo showed
signiﬁcant group effects in mPFC [23 voxels, peak Talairach co-
ordinates (x, y, z): −4, 52, 20; BA 10/9] and precuneus reaching
into PCC [11 voxels, peak Talairach co-ordinates (x, y, z): 0,
−52, 26; BA 31/7) (Fig. 3A). Post hoc analyses showed that the
group effect in mPFC was due to signiﬁcantly decreased acti-
vation in ASD compared with controls (P < 0.0001) and ADHD
(P < 0.0001), who did not differ from each other. In precuneus,
both the ADHD (P < 0.005) and ASD (P < 0.05) groups, who
did not differ from each other, had signiﬁcantly decreased acti-
vation compared with controls.
To test whether group effects were related to performance
or behavior, we correlated the statistical BOLD response in the
group difference clusters with perseverative errors and behav-
ioral scores within each group. The activation in precuneus in
ASD was positively correlated with perservative errors (r = 0.5,
P < 0.05). No other correlations were signiﬁcant.
Between-Group Differences Between Controls
and Patients Under Fluoxetine
ANCOVA between controls and patients under Fluoxetine
showed a signiﬁcant group effect in left insula reaching into
putamen [23 voxels, peak Talairach co-ordinates (x, y, z): −33, 19,
4; BA 13) (Fig. 3B). Post hoc analyses showed that this difference
was due to signiﬁcantly reduced activation in the ASD group com-
pared with controls (P < 0.005), who did not differ from ADHD.
Repeated-measures t-tests showed a signiﬁcant effect of drug
condition in mPFC (P = 0.003), which was due to signiﬁcantly
increased activation in mPFC in the ASD group under Fluoxetine
relative to placebo. A signiﬁcant drug effect was also observed
in precuneus (P < 0.05), which was due to signiﬁcantly in-
creased activation in this region in the ADHD group under
Fluoxetine relative to placebo. No other signiﬁcant normaliza-
tion effects were observed.
Correlation analyses showed that the (reduced) activation in
left insula in ASD was negatively correlated with scores on the
social domain of the ADI (r =−0.5, P < 0.05). No other corre-
lations were signiﬁcant.
To assess the potential impact of IQ on case-control group
differences, all analyses were repeated with IQ as a covariate.
All clusters remained at P < 0.05 for placebo and at P < 0.02 for
Fluoxetine.
Within-Patient Group by Medication Interaction Effects
Repeated-measures ANCOVA showed a signiﬁcant group by
medication interaction effect in mPFC [41 voxels, peak Talair-
ach co-ordinates (x, y, z): 0, 63, 15; BA 10/9), due to Fluoxetine
increasing activation in this area in the ASD group and decreas-
ing it in the ADHD group (Fig. 3C). This remained signiﬁcant
when IQ was covaried for.
Discussion
This study shows that, during the ﬁnal stage of reward reversal,
contrasted with probabilistic errors, ASD boys have disorder-
speciﬁc underactivation in mPFC, a key region of reward-related
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decision-making, relative to ADHD and control boys, and also
shared underactivation with ADHD boys, relative to controls,
in precuneus, a key region of error processing. Fluoxetine had
an inverse, disorder-speciﬁc effect in mPFC as it increased
activation in ASD boys, leading to normalization of their
dysfunction relative to controls, but decreased activation in
ADHD boys, concomitant with deteriorated task performance
relative to controls. The ﬁndings suggest that Fluoxetine has
disorder-dissociative, inverse modulation effects on a key re-
gion of reward reversal, potentially reﬂecting differential base-
line 5-HT levels in both disorders.
ASD boys compared with the other 2 groups showed
disorder-speciﬁc underactivation in a key region of reward re-
versal (Remijnse et al. 2005; Finger et al. 2008; Mitchell et al.
2009) and reward-related decision-making (Euston et al. 2012)
that is particularly sensitive to negative feedback, mediating
Figure 2. Within-group activation for (A) Healthy controls, (B) adolescents with ADHD under either placebo or Fluoxetine, and (C) adolescents with ASD under either placebo or
Fluoxetine for the contrast of ﬁnal reversal error–probabilistic error. Axial sections showing within-group brain activation for healthy control boys, boys with ADHD under either
placebo or Fluoxetine, and boys with ASD under either placebo or Fluoxetine for the contrast of ﬁnal reversal error – probabilistic error. Talairach z co-ordinates are indicated for slice
distance (in mm) from the intercommissural line. The right side corresponds to the right side of the image.
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Figure 3. (A) Between-group and within-patient comparisons: axial sections showing the between-group ANCOVA ﬁndings between controls and patients under placebo. Shown
underneath are the statistical measures of BOLD response for each of the 3 groups for each of the brain regions that showed a signiﬁcant group effect. mPFC, medial prefrontal
cortex. Error bars indicate standard error. (B) Axial sections for the between-group ANCOVA comparison between controls and patients under Fluoxetine. (C) Axial sections showing
within-patient group by medication interaction effects. Talairach z co-ordinates are indicated for slice distance (in mm) from the intercommissural line. The right side of the image
corresponds to the right side of the brain.
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shifting away from disadvantageous responses after negative
feedback (Christakou, Brammer, et al. 2009; Ghahremani et al.
2010). Dysfunction in mPFC in ASD may be related to evidence
for abnormally increased gray matter in the mPFC in adoles-
cent boys with ASD compared with controls (Bonilha et al.
2008), indicative of poor synaptic pruning and of poor 5-HT
binding in mPFC in ASD adolescents (Makkonen et al. 2008).
Although ASD patients were not signiﬁcantly impaired in the
task, they had numerically more perseverative errors with a
medium effect size (0.48), which may have reached signiﬁ-
cance in a larger cohort. The disorder speciﬁcity of the brain
dysfunction to ASD was unexpected. However, the only pre-
vious fMRI study that used a similar reward reversal task and
contrast found enhanced mPFC activation in ADHD relative to
controls (Finger et al. 2008). Taken together, the ﬁndings of
these 2 studies suggest that medial underactivation may not be
a neurofunctional feature of ADHD in the context of reward re-
versal, while lateral prefrontal underactivation in ADHD
patients relative to controls is well documented during other
cognitive control tasks that are mediated by lateral prefrontal
regions (Rubia et al. 2005, 2009; Smith et al. 2006; Rubia,
Cubillo, et al. 2010; Rubia, Halari, et al. 2010; Rubia 2011; Hart
et al. 2013).
It is interesting that, during placebo, only individuals with
ASD had reduced mPFC activation while ADHD patients did
not differ from controls. There is consistent evidence that
ADHD patients have abnormal activation in more lateral
prefrontal-striato-parietal circuitries, most prominently in
inferior prefrontal cortex and caudate during tasks of cognitive
control, attention, switching, and timing (Rubia et al. 1999,
2005, 2011; Smith et al. 2006, 2008; Rubia, Cubillo, et al. 2010;
Hart et al. 2012, 2013). Therefore, the evidence for functional
deﬁcits in ADHDpoints toward abnormalities in lateral cognitive
fronto-striato-parietal networks with relatively little evidence for
abnormalities in mPFC-limbic regions during cognitive ﬂexi-
bility or reward-related tasks. In fact, the only prior study of
reward reversal learning found increased mPFC activation in
ADHD patients during reversal errors (Finger et al. 2008). The
deﬁcits in lateral cognitive fronto-striato-parietal circuitries may
be related to evidence for delayed maturation of cortical thick-
ness in these fronto-parieto-temporal regions (Shaw et al.
2007, 2011). Adolescents and adults with ASD, on the other
hand, have more commonly been shown to have reduced acti-
vation in mPFC and their associated limbic-temporal regions
during tasks of reward, emotion processing, and cognitive
control (Schmitz et al. 2008; Di Martino et al. 2009; Uddin and
Menon 2009; Philip et al. 2012), which may be related to ab-
normal maturation patterns in ASD patients in these regions
(Cauda et al. 2011; Radua et al. 2011; Stigler et al. 2011). Chil-
dren with ASD, unlike ADHD children, who show delayed
maturation of fronto-cortical regions (Shaw et al. 2007, 2011),
undergo a period of abnormal brain overgrowth in young
childhood followed by a period of decreased growth, com-
pared with controls (Courchesne et al. 2001, 2011; Amaral
et al. 2008; Stigler et al. 2011). Hence, rather than a delay of
brain maturation like in ADHD, there is evidence for a de-
viance from normal brain maturation in ASD with early over-
growth followed by abnormal growth patterns later on in
adolescence and adulthood. Furthermore, in ASD individuals,
there is increasing evidence for abnormal white matter integ-
rity between fronto-limbic and fronto-striatal brain regions,
compared with controls (Radua et al. 2011; Langen et al. 2012;
Pardini et al. 2012; Poustka et al. 2012). This is of particular in-
terest as it has been shown that the ventromedial fronto-basal
ganglia-thalamo-cortical loops are involved in habit formation,
reward processing, and stimulus-response associations
(Packard and Knowlton 2002; Yin and Knowlton 2006; Haber
and Calzavara 2009). Although poor fronto-striatal and fronto-
parietal white matter tract connectivities have also consistently
been reported in children with ADHD, fronto-limbic structural
connectivity abnormalities have not been frequently associated
with ADHD (Konrad and Eickhoff 2010; van Ewijk et al. 2012).
Given that the mPFC is part of a fronto-striato-limbic reward
processing network, this may account for the disorder-speciﬁc
reduced mPFC activation in the ASD group.
The shared dysfunction in precuneus is interesting as this
region is closely interconnected with the mPFC (Small et al.
2003) and plays a key role in reversal learning (Dodds et al.
2008; Ghahremani et al. 2010), reward evaluation (McCoy and
Platt 2005; Liu et al. 2011), and visual–spatial attention to sal-
iency, in particular error processing (Rubia et al. 2003, 2007;
Small et al. 2003; Ridderinkhof et al. 2004; Kravitz et al. 2011).
Findings of precuneus dysfunction in ADHD during reward re-
versal learning extend prior evidence for precuneus dysfunc-
tion in response to salient events such as errors and rewarded
trials in other tasks (Rubia et al. 2005, 2009; Rubia 2011), pre-
sumably reﬂecting poor saliency and error processing. In ASD,
the precuneus has been found to be underactivated during in-
terference (Solomon et al. 2009) and motor inhibition (Kana
et al. 2007). The behavioral signiﬁcance of the abnormal precu-
neus activation in the ASD group is shown by the positive cor-
relation of this activation with perservative errors. It has been
shown that errors elicit the activation of an error detection
network that comprises anterior and posterior cingulate as
well as precuneus (Small et al. 2003; Ridderinkhof et al. 2004;
Rubia et al. 2007; Kravitz et al. 2011). ASD patients committed
more peseverative errors with a medium effect size than con-
trols, and the enhanced number of errors may be caused by the
diminished precuneus activation, given that higher precuneus
activation reﬂects better error monitoring in ASD patients.
The most intriguing ﬁnding is the inverse effect of Fluoxe-
tine on mPFC activation in the 2 disorders, upregulating and
normalizing it in ASD, but decreasing it in ADHD. This inverse
effect could potentially reﬂect disorder differences in baseline
levels of 5-HT. Approximately 30% of individuals with ASD
have enhanced platelet 5-HT levels (i.e., hyperserotonemia)
(Piven et al. 1991; Mulder et al. 2004; Hranilovic et al. 2007).
There is evidence for reduced binding to 5-HT transporters in
the mPFC of individuals with ASD (Makkonen et al. 2008; Na-
kamura et al. 2010) as well as reduced 5-HT2A receptor binding
(Murphy et al. 2006) and altered 5-HT synthesis (Chugani et al.
1997, 1999). This suggests that hyperserotonemia may be an
adaptation to counteract poor 5-HT receptor binding and ab-
normal 5-HT synthesis. An increase in 5-HT with Fluoxetine
may have increased ligand-receptor binding sufﬁciently to
enhance activation in areas, where 5-HT receptor density is ty-
pically low. In addition, Fluoxetine may have amended an ab-
normal “balance” of 5-HT, therefore improving the
homeostatic role of this key neurotransmitter and potentially
leading to an increase in mPFC activation in ASD (Di Pietro
and Seamans 2011; Murano et al. 2011). Furthermore, each
brain region has a distinct serotonergic proﬁle, with limbic and
more medial structures receiving dense serotonergic inner-
vation (Jacobs and Azmitia 1992; Varnäs et al. 2004). This
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therefore makes regions such as the mPFC highly susceptible
to serotonergic manipulation, particularly in a patient group
which have shown structural (Bonilha et al. 2008) and bio-
chemical (Murphy et al. 2006; Makkonen et al. 2008; Naka-
mura et al. 2010) abnormalities in this region. It is also
plausible that an increase in 5-HT may be modulating primary
5-HT abnormalities in transporter function (Makkonen et al.
2008; Nakamura et al. 2010) or 5-HT2A receptor binding
(Murphy et al. 2006), which have been reported to be impaired
in the mPFC of ASD individuals (Murphy et al. 2006; Makko-
nen et al. 2008; Nakamura et al. 2010), and may have led to the
increased activation in mPFC observed in the ASD group. Our
ﬁnding of an upregulation and normalization of Fluoxetine in
the mPFC of adolescents with ASD extends prior evidence that
SSRIs increase metabolic and neurofunctional activities in pre-
frontal areas in adults with ASD (Buchsbaum et al. 2001;
Dichter et al. 2010).
Fluoxetine also decreased insula activation in ASD relative
to controls. There is consistent evidence for underactivation
and underconnectivity of the insula in individuals with ASD
(Uddin and Menon 2009; Ebisch et al. 2011). However, this
was mainly observed during tasks of emotion processing and
there is evidence that this underactivation is associated with
alexithymia in ASD, as opposed to social interaction deﬁcits
(Bird et al. 2010). The insula forms part of a mPFC-striato-
limbic network for reward-related decision-making and, like
mPFC, is particularly sensitive to negative feedback and med-
iates shifting away from disadvantageous choices in both gam-
bling (Christakou, Brammer, et al. 2009; Christakou et al.
2013) and reward reversal learning tasks (O’Doherty et al.
2003; Remijnse et al. 2005; Cohen et al. 2008). The normaliza-
tion of mPFC activation with Fluoxetine may have resulted in
the impairment of a limbic part of the reversal network,
suggesting that brain function was not entirely normalized.
Alternatively, insula activation has been observed in uncertain
conditions during probabilistic tasks (Huettel et al. 2005) and
is associated with anxiety to the anticipation of aversive stimuli
(Paulus and Stein 2006; Simmons et al. 2006), both of which
are key aspects of reward reversal learning. Therefore, the de-
creased activation in this area in ASD boys may have been a re-
ﬂection of a reduction in their anxiety to the negative feedback
they received when they reversed their response. This is in line
with the behavioral correlations which found that the higher
the social impairment on the ADI subscale, and therefore the
more anxious the individual is likely to be, the more Fluoxetine
decreased insula activation.
The reduction of activation in mPFC in ADHD with Fluoxe-
tine was unexpected. However, ADHD boys, unlike ASD boys,
showed no underactivation in this region, and hence, the 5-HT
modulation may have interfered with normal prefrontal acti-
vation. This is further supported by the ﬁnding of performance
impairment with 5-HT in ADHD. While ADHD patients have
shown lateral prefronto-striatal underactivation during switch-
ing tasks (Smith et al. 2006; Rubia, Cubillo, et al. 2010; Rubia,
Halari, et al. 2010), the only previous fMRI study on a similar
contrast in a reward reversal task found increased mPFC acti-
vation in ADHD relative to controls (Finger et al. 2008). Hence,
reward reversal tasks may not elicit underactivation in key
areas of reversal processes and therefore not tap into the dys-
functional brain mechanisms of ADHD. Furthermore, although
there is evidence of serotonergic dysfunction in ADHD at both
a genetic (Gizer et al. 2009) and biochemical (Spivak et al.
1999) level, potentially leading to low 5-HT, the positive clini-
cal effect of Fluoxetine monotherapy (Barrickman et al. 1991;
Quintana et al. 2007) and the modulating effect of Fluoxetine
on Methylphenidate therapy (Gammon and Brown 1993; Find-
ling 1996) may be due to the interaction between the increase
in 5-HT, a key regulatory neurotransmitter, and dopamine, a
neurotransmitter which is known to be low in individuals with
ADHD (Volkow et al. 1998; del Campo et al. 2011). Studies in
rats have found that increased impulsivity is associated with
5-HT levels in the mPFC, highlighting the importance of 5-HT
in this area in disorders of inhibition and impulsivity, and it is
known that both 5-HT and dopamine are involved in inhibition
(Dalley et al. 2002, 2008). Antagonism of the 5-HT2C receptor,
leading to less 5-HT-mediated inhibition of dopamine release,
leads to better reversal learning in rats and shows that the inter-
play between 5-HT and dopamine, as well as absolute 5-HT
levels, is involved in reversal learning (Boulougouris et al.
2007). Interestingly, a decrease in 5-HT with acute tryptophan
depletion has been shown to lead to increased activation in the
mPFC of healthy individuals during a task of reward reversal
learning (Evers et al. 2005). Therefore, it appears as if 5-HT
agonists may perturb the delicate serotonin-dopamine balance
in mPFC, an area which is normal in ADHD in this task
context, leading to decreased activation. Given that 11 ADHD
patients were withdrawn from medication for 48 h, it cannot
be excluded that the withdrawal effect or the interaction of the
dopamine withdrawal effect combined with the acute SSRI
effect may have affected brain activation or performance
(Schweren et al. 2012).It is also possible that the long-term
effect of stimulant medication on brain structure and function
(Nakao et al. 2011; Hart et al. 2012, 2013; Rubia et al. 2013) in
the 11 medicated ADHD participants may have inﬂuenced the
ﬁndings. However, both withdrawal and long-term stimulant
effects would have been contrasted out by the placebo control
condition.
In ASD, however, 5-HT is thought to be the main abnormal
neurotransmitter in the disorder, and there is a wealth of re-
search supporting the presence of genetic and biochemical ser-
otonergic abnormalities, leading to high levels of 5-HT (Piven
et al. 1991; Chugani et al. 1997, 1999; Mulder et al. 2004;
Murphy et al. 2006; Hranilovic et al. 2007; Makkonen et al.
2008; Zafeiriou et al. 2009; Nakamura et al. 2010), in addition
to the positive effect of Fluoxetine on stereotyped behaviors
(Fatemi et al. 1998; Hollander et al. 2005, 2012; Carrasco et al.
2012) and brain activation in areas related to reward reversal
(Buchsbaum et al. 2001; Dichter et al. 2010) in children and
adults with ASD. These differing biochemical abnormalities
may have accounted for the positive upregulation effect of
Fluoxetine on ASD mPFC activation and its negative downre-
gulating effect on mPFC activation in ADHD.
Despite signiﬁcant effects on brain activation in both ADHD
and ASD boys, Fluoxetine only had a behavioral effect in the
ADHD group when compared with controls, leading patients
to perform worse than controls under Fluoxetine, but not
placebo. It has previously been shown in similar reward rever-
sal learning tasks that brain function is more sensitive to
pharmacological manipulations than performance (Evers et al.
2005). In addition, although a sample size of 15–18 is adequate
for fMRI analysis (Thirion et al. 2007), it is likely to be insufﬁ-
cient to detect more subtle neuropsychological differences,
such as those that may be present between the ASD and
control group.
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The strengths of this study are the carefully selected, nonco-
morbid patient groups and the medication-naivety of the ASD
group. Although there is a signiﬁcant clinical overlap between
ADHD and ASD (van der Meer et al. 2012; Rao and Landa 2013),
rigorous screening ensured that no overlap was present between
the 2 patient groups in this study. Although at the time of study
DSM-V was not available, andmight have enabled easier identiﬁ-
cation and exclusion of comorbid cases, we are conﬁdent that
our rigorous screening ensured that none of the patients had co-
morbidity with the other disorder. This is of great importance as
there is an increasing need to ﬁnd objective, biological bio-
markers with the potential to aid in the differential diagnosis of
these 2 neurodevelopmental disorders. While testing clearly non-
comorbid patient groups is an advantage for studies such as our
own which aim to elucidate the differences and commonalities
in neural substrates and drug manipulations between the 2 dis-
orders, a limitation is that the data cannot be generalized to the
commonly occurring overlapping disorder type. Future studies
should compare pure disorder groups as well as comorbid con-
ditions in order to disentangle the underlying neural substrates
of these and the effect of serotonin manipulations.
A limitation is the lower IQ in the ADHD group. However,
covariance analysis showed that this did not affect the main ﬁnd-
ings. The use of an acute dose of Fluoxetine may be considered
another limitation. However, studies on acute dose effects have
the advantage to allow to investigate brain activation effects of
medication without the confound of side effects and long-term
chronic effects on behavior and cognition, and are often a
necessary ﬁrst step for proof of concept. However, they are
limited in that they cannot investigate the association between
brain activation effects and clinical improvement over a longer
period of time such as several weeks, which is when Fluoxetine
typically starts to show clinical efﬁcacy. This is an area which
should be focused on in future research, particularly as pro-
tracted courses of Fluoxetine are used in the clinical trials that
report an improvement in behavior in ADHD (Barrickman et al.
1991; Gammon and Brown 1993; Quintana et al. 2007) and ASD
children (DeLong et al. 1998, 2002; Hollander et al. 2005). In
addition, the mechanisms of action of these long-term effects
need also be understood. Another limitation is that both patient
groups were scanned twice, while controls were only scanned
once. While training effects are counter-balanced between medi-
cation conditions, it cannot be ruled out that the fact that
patients conducted the task twice might have affected the per-
formance or brain activation ﬁndings.
To summarize, we found disorder-speciﬁc underactivation
in ASD boys in mPFC, a key region of reversal learning, as well
as disorder-dissociated inverse effects of Fluoxetine on this
region, which upregulated and normalized dysfunction in ASD
but down-regulated activation in ADHD, concomitant with
worsening their task performance. The ﬁndings may indicate
dissociated underlying 5-HT abnormalities in the 2 disorders.
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